title: The significance of immunocompromised condition in the prophylaxis of hepatitis B in chronic renal insufficiency.
abstract: The paper presents the immunogenicity of hepatitis vaccine (obtained by genetic engineering) in immunocompromised patients with preterminal renal insufficiency defined by depression of creatinine clearance of 10 to 25 ml/min. The study consisted of 28 randomized patients with impaired renal function. Sixteen patients received a single dose and, twelve a double dose of vaccine. Revaccination following 3 intramuscular doses of vaccine had been undertaken after 24 weeks if antibodies were not detected or their titer was 10 i. u. or less. All patients obtained a booster dose following 52 weeks. There was no statistically significant difference in titer values between immunocompromised patients regardless of whether they were vaccinated with a single or double dose. The antibody titer in patients with chronic renal insufficiency was significantly lower as compared with the results of vaccination in healthy population. It may be concluded that it is more beneficial and less expensive to use a single dose vaccine and revaccination if the titer is negative or insufficiently high.
authors.affiliation: University Department of Emergency Medicine, Hemodialysis Centre, Medical Faculty, University of Zagreb, Croatia.
authors.forename: V
authors.initials: V
authors.lastname: Gasparović
authors.forename: D
authors.initials: D
authors.lastname: Puljević
authors.forename: M
authors.initials: M
authors.lastname: Gjurasin
authors.forename: N
authors.initials: N
authors.lastname: Delimar
authors.forename: D
authors.initials: D
authors.lastname: Borcić
authors.forename: H
authors.initials: H
authors.lastname: Gasparović
authors.forename: I
authors.initials: I
authors.lastname: Mihaljević
mesh_terms: D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000096:biosynthesis; D017325:Hepatitis B Vaccines / Q000008:administration & dosage* / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D016867:Immunocompromised Host; D007676:Kidney Failure, Chronic / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000008:administration & dosage* / Q000276:immunology
chemical_list: C075654:Engerix-B; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic